Belgian Cancer Registry

CANCER FACT SHEET 2024

INVASIVE TUMOURS

ICD-10 C00-C43; C45-C97 + MDS & MPN

Key facts

- **78,697** new diagnoses in 2024
- **25,836** deaths* due to cancer in 2023
- 5-year net survival of **70.6%**

*Mortality excluding MDS & MPN

Lifetime risk (0-84 years)

53.4 in 100 males

41.2 in 100 females









Belgian Cancer Registry

INCIDENCE

Age-specific incidence, 2020-2024



Incidence by region



- Median age at diagnosis for cancer is **69 years**
- There is a **higher risk** of cancer diagnosis **in Wallonia**, compared to the other regions
- **Prostate and Breast** cancer are the most common cancers in males and females, respectively

10 most common cancers



Belgian Cancer Registry

INCIDENCE TRENDS & SURVIVAL

Age-standardised incidence and mortality, 2004-2024



- Cancer is **more common in males** than in females; male to female ratio of 1.2
- The average annual percentage change of the risk of a **cancer diagnosis in males** is **−0.1%**
- The average annual percentage change of the risk of a **cancer diagnosis in females** is **+0.7%**
- Risk of a **cancer mortality in males is decreasing** with an average annual percentage change of **−2.2%**
- Risk of a **cancer mortality in females is decreasing** with an average annual percentage change of **−1.0%**

Age-standardised incidence trends



Net survival by age, 2015-2024



Belgian Cancer Registry

DATA FLOW



The Belgian Cancer Registry receives data from several sources:

- Oncological and paediatric haemato-oncology centres, also called **'clinical network'**, provide notification and registration of all malignant tumours known in their care program.
- Laboratories for pathological anatomy, also called **'pathological network'**, provide notification and registration including pathological reports of microscopically confirmed cancer diagnoses. Using these reports, the Belgian Cancer Registry performs quality control on the data from the oncological programs and the paediatric centres.
- **The Crossroads Bank for Social Security** provides additional data on vital status.





- **Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.
- **Cancer maps:** Cities with at least 150,000 inhabitants are directly represented on the map as circles with a diameter relative to the population size, and a colour shading indicating the actual calculated ESR2013 in that city. The 19 municipalities of the Brussels Capital Region (more than 1,000,000 inhabitants) are divided in three separate circles, based on socio-economic parameters. The socio-economic status is lowest in the westernmost circle and highest in the easternmost circle. Methodological information is available in 'Cancer burden in Belgium 2004-2017, Belgian Cancer Registry, Brussels, 2020'.
- **Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).
- **ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.
- **Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).
- The net survival estimation was based on the regional lifetables 2024, obtained from Statbel.
- **Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.
- **95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.
- **MDS & MPN:** Myelodysplastic syndrome and myeloproliferative neoplasm
- **The inclusion criteria** of this cancer fact sheet are all cancers except non-melanoma skin cancers. We strive towards a registration of cancer incidence that is as complete as possible, including non-melanoma skin cancers. However, we are aware that a complete registration of these types of skin cancer is complex. Since there are a large number of these tumours and because most of these skin cancers are not life-threatening for the patient, they are, in contrast with other malignant neoplasms, not always registered in detail by all our sources.

**Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.*